Global

Are These Stocks A Sure Bet? – MetLife, Inc. (MET), Voyager Therapeutics, Inc. (VYGR)

The shares of MetLife, Inc. have decreased by more than -7.00% this year alone. The shares recently went down by -1.71% or -$0.82 and now trades at $47.02. The shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR), has jumped by 46.27% year to date as of 03/12/2018. The shares currently trade at $24.28 and have been able to report a change of -22.33% over the past one week.

The stock of MetLife, Inc. and Voyager Therapeutics, Inc. were two of the most active stocks on Monday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

Profitability and Returns

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. MET has an EBITDA margin of 6.95%, this implies that the underlying business of MET is more profitable. The ROI of MET is 7.50% while that of VYGR is -30.40%. These figures suggest that MET ventures generate a higher ROI than that of VYGR.



Cash Flow 

The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, MET’s free cash flow per share is a positive 0, while that of VYGR is negative -0.14.

Liquidity and Financial Risk




The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The debt ratio of MET is 0.33 compared to 0.00 for VYGR. MET can be able to settle its long-term debts and thus is a lower financial risk than VYGR.

Valuation

MET currently trades at a forward P/E of 8.71, a P/B of 0.84, and a P/S of 0.78 while VYGR trades at a P/B of 7.45, and a P/S of 105.66. This means that looking at the earnings, book values and sales basis, MET is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

Analyst Price Targets and Opinions

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of MET is currently at a -14.29% to its one-year price target of 54.86. Looking at its rival pricing, VYGR is at a -20.39% relative to its price target of 30.50. This figure implies that over the next one year, VYGR is a better investment.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), MET is given a 2.40 while 1.60 placed for VYGR. This means that analysts are more bullish on the outlook for MET stocks.

Insider Activity and Investor Sentiment

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for MET is 1.78 while that of VYGR is just 4.60. This means that analysts are more bullish on the forecast for MET stock.

Conclusion

The stock of Voyager Therapeutics, Inc. defeats that of MetLife, Inc. when the two are compared, with VYGR taking 6 out of the total factors that were been considered. VYGR happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, VYGR is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for VYGR is better on when it is viewed on short interest.

Previous ArticleNext Article

Related Post

Curis, Inc. (CRIS) vs. Acorda Therapeutics, Inc. (... Curis, Inc. (NASDAQ:CRIS) shares are down more than -35.69% this year and recently increased 2.81% or $0.01 to settle at $0.45. Acorda Therapeutics, I...
Which Market Offer More Value? – Extreme Net... The shares of Extreme Networks, Inc. have increased by more than 20.45% this year alone. The shares recently went up by 9.59% or $1.32 and now trades ...
Set Sail With Microsoft Corporation (MSFT), Sirius...   The shares of Microsoft Corporation have increased by more than 8.55% this year alone. The shares recently went down by -0.98% or -$0.92 and...
Choosing Between Hot Stocks: Macy’s, Inc. (M... The shares of Macy's, Inc. have increased by more than 1.59% this year alone. The shares recently went down by -0.23% or -$0.06 and now trades at $25....
A Comparison of Top Movers: ABIOMED, Inc. (ABMD), ... The shares of ABIOMED, Inc. have increased by more than 36.32% this year alone. The shares recently went up by 9.18% or $21.48 and now trades at $255....